Roche raised the curtain on its novel approach to DNA sequencing earlier this year, and now it's working with the Broad ...

Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently ...

Genmab has shared the first data on rinatabart sesutecan (Rina-S) in advanced endome | Genmab has shared the first data on ...

Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair ...

Innate Pharma has claimed long-term data from a phase 2 study show that its anti-KIR3DL2 antibody has a “sustained effect” ...

With Illumina currently banned from shipping its DNA sequencers into China—in retaliation for the Trump administration’s ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Earlier this year, Cullinan said its lead candidate hit the bull's-eye in a midstage lung cancer cancer trial but stayed mum on the details. Now, the biotech is revealing the results that have ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Despite Merck KGaA’s lupus drug failing to prove itself against one form of the autoimmune disease, the German drugmaker has ...

Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win ...